DexCom - DXCM Stock Forecast, Price & News

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Trading Up 1.8 %

NASDAQ:DXCM opened at $89.83 on Friday. The stock has a fifty day moving average price of $78.92 and a two-hundred day moving average price of $94.89. The stock has a market capitalization of $35.27 billion, a price-to-earnings ratio of 187.15, a PEG ratio of 3.59 and a beta of 1.03. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.30 and a current ratio of 4.72. DexCom has a 1 year low of $66.89 and a 1 year high of $164.86.

DexCom (NASDAQ:DXCM - Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The business had revenue of $696.20 million during the quarter, compared to analysts' expectations of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The company's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 EPS. As a group, sell-side analysts anticipate that DexCom will post 0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Piper Sandler cut their target price on shares of DexCom from $120.00 to $110.00 and set an "overweight" rating on the stock in a research note on Friday, July 29th. Morgan Stanley cut their target price on shares of DexCom from $91.00 to $83.00 and set an "equal weight" rating on the stock in a research note on Friday, July 29th. SVB Leerink cut their target price on shares of DexCom from $141.25 to $125.00 in a research note on Friday, April 29th. BTIG Research lowered their price target on DexCom from $135.00 to $105.00 and set a "buy" rating for the company in a report on Friday, June 24th. Finally, Canaccord Genuity Group lowered their price target on DexCom from $131.25 to $125.00 in a report on Friday, April 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $115.23.

Insiders Place Their Bets

In other news, Director Steven Robert Pacelli sold 250 shares of the firm's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $296.33, for a total value of $74,082.50. Following the completion of the transaction, the director now owns 35,175 shares in the company, valued at $10,423,407.75. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Steven Robert Pacelli sold 250 shares of the firm's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $296.33, for a total value of $74,082.50. Following the completion of the transaction, the director now owns 35,175 shares in the company, valued at $10,423,407.75. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jereme M. Sylvain sold 600 shares of the firm's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $301.57, for a total value of $180,942.00. Following the completion of the transaction, the chief financial officer now owns 17,408 shares of the company's stock, valued at approximately $5,249,730.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,850 shares of company stock worth $410,645. 0.41% of the stock is owned by corporate insiders.